

Abstract

The present invention provides therapeutic agents for corneal disorders comprising compounds having effects of activating Rho as active ingredients, for example corneal epithelial migration promoters. The compounds having the effects of activating Rho are exemplified by lysophosphatidic acid and acyl derivatives thereof. The corneal disorders are exemplified by corneal ulcer, corneal erosion, keratitis and dry eye.